S. Mizutani et al., POSSIBLE EFFECTS OF PLACENTAL LEUCINE AMINOPEPTIDASE ON THE REGULATION OF BRAIN-GUT HORMONES IN THE FETOPLACENTAL UNIT, Biology of the neonate, 69(5), 1996, pp. 307-317
The hydrolysis of somatostatin by human placental subcellular fraction
s and pregnancy sera was studied in the presence of selective inhibito
rs and the antibody against pregnancy serum oxytocinase (placental leu
cine aminopeptidase; EC3.4.11.3) by measuring the released amino acids
by high-performance liquid chromatography. We also studied the degrad
ation of other brain-gut hormones, such as glucagon, growth hormone, g
rowth hormone releasing factor, and insulin, in the human placenta and
found that the human placenta degrades somatostatin, glucagon, and gr
owth hormone releasing factor, but not insulin and growth hormone. The
degradation velocity of somatostatin was ten times greater than that
of growth hormone releasing factor in placental microsomal fractions.
Our data suggest that the stimulatory control by growth hormone releas
ing factor is dominant in the fetal growth hormone secretion. Our data
also identified the somatostatin-degrading protease in human placenta
using placental leucine aminopeptidase. It is known that the mean som
atostatin levels in the umbilical artery are about 2.5-fold higher tha
n those in the umbilical vein. Our data on somatostatin levels in umbi
lical artery and vein of intrauterine growth retardation human fetuses
showed that the ratio umbilical artery/vein is around 1. Since insuli
n is known to be the primary hormone regulating the ratio of fetal gro
wth, our data suggest that the degradation of somatostatin in the plac
enta is decreased and that elongation of somatostatin effects may resu
lt in the inhibition of insulin secretion in the intrauterine growth r
etardation fetus.